Skip to content

Clinical trials

Hyperthyroidism trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hyperthyroidism Clear all

108 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20043
20052
20073
20083
20092
20105
20111
20124
20132
20146
20154
20166
20172
20184
20196
20203
202111
20225
20236
20247
202510
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed50
Unknown status25
Recruiting16
Not yet recruiting5
Terminated4
Active, not recruiting3
Enrolling by invitation2
Withdrawn2
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University Hospital, Basel, Switzerland3
Biohaven Therapeutics Ltd.2
Centre Hospitalier Princesse Grace2
Hospital de Clinicas de Porto Alegre2
IRCCS Azienda Ospedaliero-Universitaria di Bologna2
Immunovant Sciences GmbH2
Mashhad University of Medical Sciences2
Mayo Clinic2
Medical University of Warsaw2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hyperthyroidism108
Graves Disease34
Hypothyroidism20
Thyroid Diseases15
Thyroid Neoplasms10
Graves Ophthalmopathy8
Thyrotoxicosis8
Thyroid Nodule6
Atrial Fibrillation5
Goiter5

Trials

Showing 1 to 25 of 108. Each trial links to its page on Pharma Observatory.

8 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.